← Back to Search

GLP-1 Receptor Agonist

Survodutide for Obesity

Orlando, FL
Phase 1
Waitlist Available
Research Sponsored by Boehringer Ingelheim
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Age of 18 to 65 years (inclusive)
Male or female subjects with obesity (BMI ≥30 and ≤45 kg/m²)
Must not have
History of chronic liver disease / cirrhosis
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
No Placebo-Only Group

Summary

"This trial is for adults aged 18-65 with obesity and a BMI between 30-45. The study aims to see if a new medicine called survodutide helps the body use energy

See full description
Who is the study for?
Adults aged 18-65 with obesity (BMI of 30-45 kg/m²) can join this study. Women must use effective birth control, and participants should be able to self-inject the medication or have someone who can do it for them. They need to follow lifestyle advice and trial procedures throughout the study.Check my eligibility
What is being tested?
The trial is testing Survodutide against Semaglutide in people with obesity to see if it improves energy usage and fat breakdown. Participants are randomly assigned to receive one of these drugs via weekly injections for about 8 months, with regular health checks and tests measuring oxygen intake and carbon dioxide output.See study design
What are the potential side effects?
Potential side effects aren't specified here, but typically medications like Survodutide and Semaglutide may cause digestive issues, changes in appetite, injection site reactions, nausea, or increased heart rate. Regular health checks will monitor for any unwanted effects.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am between 18 and 65 years old.
 show original
Select...
My BMI is between 30 and 45.
 show original

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have a history of chronic liver disease or cirrhosis.
 show original

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Side effects data

From 2023 Phase 2 trial • 295 Patients • NCT04771273
65%
Nausea
41%
Vomiting
41%
Diarrhoea
23%
Headache
22%
Decreased appetite
20%
COVID-19
19%
Fatigue
17%
Constipation
16%
Abdominal distension
15%
Dyspepsia
13%
Abdominal pain
13%
Eructation
12%
Dizziness
9%
Flatulence
9%
Back pain
9%
Gastrooesophageal reflux disease
8%
Upper respiratory tract infection
8%
Hypoglycaemia
8%
Abdominal pain upper
8%
Urinary tract infection
6%
Nasopharyngitis
5%
Asthenia
5%
Lipase increased
5%
Cough
4%
Arthralgia
4%
Pyrexia
4%
Myalgia
3%
Injection site reaction
3%
Injection site bruising
3%
Injection site pain
2%
Early satiety
2%
Malaise
2%
Influenza
2%
Insomnia
1%
Anaemia
1%
Intracranial aneurysm
1%
Acute kidney injury
1%
Sinusitis
1%
Angioedema
1%
Abnormal uterine bleeding
1%
Pain in extremity
1%
Rash
1%
Carotid artery stenosis
1%
Hypertensive crisis
1%
Hyperglycaemia
1%
Enteritis
1%
Cerebral infarction
1%
Lumbar spinal stenosis
1%
Combined pulmonary fibrosis and emphysema
100%
80%
60%
40%
20%
0%
Study treatment Arm
Placebo - Actual Maintenance Treatment
Survodutide 2.4 mg - Actual Maintenance Treatment
Survodutide 4.8 mg - Actual Maintenance Treatment
Survodutide 6.0 mg - Actual Maintenance Treatment

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Survodutide armExperimental Treatment1 Intervention
Group II: Semaglutide armActive Control1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Survodutide
2021
Completed Phase 2
~300

Find a Location

Closest Location:Pennington Biomedical Research Center· Baton Rouge, LA· 633 miles

Who is running the clinical trial?

Boehringer IngelheimLead Sponsor
2,560 Previous Clinical Trials
15,897,742 Total Patients Enrolled
22 Trials studying Obesity
10,264 Patients Enrolled for Obesity
~40 spots leftby May 2026
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top